The timing, you have to admit, looks choreographed.
Just eight days after cutting the ribbon on a sprawling 30,000-square-foot facility in Palmetto, Florida—complete with surgeon training theaters and manufacturing lines—OSSIO locked down a $50 million credit facility on February 11, 2026. The Israeli-American medtech company, which wants to replace metal screws and pins with implants that actually become bone, has now pulled in more than $75 million in combined debt and equity financing in a stretch of barely ten weeks.
That kind of velocity suggests something's working.
Horizon Technology Finance and Monroe Capital structured the credit line, providing $40 million upfront with another $10 million on standby. Neither OSSIO nor the lenders disclosed interest rates or covenant thresholds, though in medtech circles that's standard practice until quarterly filings force disclosure. What's less standard is the capital cadence: the debt facility follows a $27.6 million Series D equity round that closed in December 2024, led by Questa Capital. Seventy-five days. Two major closes.
"We're scaling aggressively," the moves seem to telegraph, though perhaps more aggressively than even management anticipated when they first broke ground in Florida last September.
The Florida Gambit
OSSIO's new U.S. headquarters isn't just office space—it's a statement about where founder Orahn Preiss-Bloom and CEO Brian Verrier (a Covidien and Medtronic alum) see the center of gravity shifting. While R&D remains anchored in Caesarea, Israel, where Preiss-Bloom launched the company in 2014, the commercial engine now hums in Florida. The site is projected to generate roughly 100 jobs over five years, assuming the market responds as OSSIO expects.
And there are reasons to think it might. The company targets a roughly $16 billion orthopedic fixation market still dominated by permanent metal hardware—titanium and stainless steel screws, pins, staples that do their job, then stick around indefinitely. Or don't stick around: one Finnish registry study found surgeons removed hardware in 27% of ankle fracture cases, often because the metal caused irritation, infection risk, or simply felt foreign to patients.
Enter OSSIOfiber, the company's mineral fiber matrix platform. The implants provide rigid fixation during the critical healing window, then gradually integrate with surrounding bone tissue and are replaced—actually replaced—by the patient's own skeletal structure. It's regenerative orthopedics, not just mechanical fixation.
Since the FDA cleared OSSIO's first product in January 2019, the company has racked up between 60,000 and 65,000 cumulative implant uses across the U.S. That's not trivial for a technology asking surgeons to rethink decades of metal-first training. The portfolio has expanded through multiple 510(k) clearances: compression screws, staples, suture anchors, trimmable fixation nails. A pediatric indication cleared in December 2023 opened the door to patients as young as two years old—a segment where avoiding permanent metal makes intuitive sense to parents and physicians alike.
Capital Meets Capacity
But products don't sell themselves, especially in orthopedics where surgeon preference drives adoption and hospital systems move cautiously on new technologies. Which brings us back to that $50 million credit line.
The debt financing gives OSSIO breathing room to scale distribution networks, train more surgeons at the Florida facility, and perhaps most critically, avoid diluting existing equity holders while the company works toward profitability. Medtech companies often turn to debt once revenue momentum justifies it—a signal that OSSIO believes its commercial traction has reached an inflection point.
The company does hold one meaningful tailwind: a three-year group purchasing organization contract with Vizient, which provides negotiated pricing access to thousands of U.S. hospitals and ambulatory surgery centers. GPO contracts don't guarantee adoption, but they remove a significant barrier, letting OSSIO get on formularies and into surgeon hands without fighting facility-by-facility procurement battles.
Still, questions linger. How fast can the company convert early adopters into mainstream users? Will reimbursement dynamics—always thorny in orthopedics—support premium pricing for bio-integrative technology over commodity metal hardware? And can OSSIO sustain the burn rate implied by this capital sprint while building toward cash flow breakeven?
What Happens Next
For now, OSSIO seems focused on execution rather than existential questions. With Israeli R&D feeding the innovation pipeline and U.S. manufacturing now operational, the company is positioned to accelerate product rollout. Whether that's enough to fundamentally shift orthopedic practice away from metal—a material surgeons have trusted for generations—remains the central drama.
The $50 million credit facility buys time and capacity. What OSSIO does with both will determine whether this becomes a footnote in medtech history or the start of something larger. The company's betting on the latter, and at this stage, capital providers seem willing to take that bet alongside them.
Just perhaps not as many more bets, not for a while. Seventy-five million dollars doesn't last forever, even in medtech.
